27
Participants
Start Date
June 26, 2018
Primary Completion Date
November 12, 2020
Study Completion Date
November 12, 2020
AG-348
"Part 1 (Dose Optimization Period): Participants began by receiving 5 mg orally, BID. Each participant's dose of AG-348 was sequentially increased to 20 mg BID followed by 50 mg BID depending on their response to AG-348 and their tolerance.~Part 2 (Fixed Dose Period): Optimized dose determined in Part 1."
University of Copenhagen, Herlev Hospital, Herlev
Universitair Medisch Centrum Utrecht, Utrecht
Department of Paediatrics and Thalassaemia Center, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok
Hôpital de la Timone, Marseille
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan
Emory University, Atlanta
AORN Cardarelli, Napoli
Ospedale Galliera, Napoli
"AOU Policlinico, Università della Campania Luigi Vanvitelli", Napoli
Hopital Universitaire Henri Mondor, Créteil
UCSF Benioff Children's Hospital, Oakland
Seattle Cancer Care Alliance, Seattle
Massachusetts General Hospital, Boston
Toronto General Hospital, University Health Network, Toronto
St James's Hospital Department of Haematology, Dublin
Addenbrooke's Hospital, Cambridge
Imperial College Healthcare NHS Trust, Hammersmith Hospital, London
University College London, London
Manchester Royal Infirmary, Manchester
Lead Sponsor
Agios Pharmaceuticals, Inc.
INDUSTRY